Please login to the form below

Not currently logged in
Email:
Password:

IGAS

This page shows the latest IGAS news and features for those working in and with pharma, biotech and healthcare.

Morning brief: Sanofi's shaky start, pharma begins talks with UK government and more

Morning brief: Sanofi's shaky start, pharma begins talks with UK government and more

This is the second breakthrough therapy drug designation for OMS721, which gained the status last year for treatment of Immunoglobulin A (IgA) nephropathy, in which pivotal phase III trials recently begun.

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics